

# **Research Assignment**

**Treatment of Hypercholesterolaemia with Simvastatin.  
Evaluation of Herbs and Nutrients for Adjunct or Alternative  
Treatment.**

**Author: Stephanie Rother**  
**Endeavour College of Natural Health**  
(formerly Australian College of Natural Medicine)

**Student No. 217001**

**2008**

Word Count: 2836  
(excluding in-text references, tables and headings)

# Table of Contents

1	Introduction	3
2	Conventional Drug Therapy with Simvastatin	3
2.1	Pharmacology of ingredients	3
2.2	Main Indications and costs	4
2.3	Safety Issues	4
2.3.1	Contraindications	4
2.3.2	Interactions	5
2.3.3	Adverse Reactions	5
3	Integrative Approach - Possible Interactions and Potentiations with Natural Medicine	5
3.1	Nutritional	5
3.1.1	Fish Oil	5
3.1.2	Co-Enzyme Q10	5
3.1.3	Policosanol	7
3.1.4	Red Yeast Rice	7
3.1.5	Vit B <sub>3</sub> (Niacin)	8
3.1.6	Probiotics	8
3.1.7	Plant Sterols	8
3.1.8	Soy Protein	9
3.2	Herbal	9
3.2.1	Cynara scolymus	9
3.2.2	Garlic	11
3.2.3	Commiphora mol mol	12
4	Fibre as a Possible Natural Therapy Alternative	12
4.1	Efficacy	12
4.2	Adverse Effects of Fibre	14
4.3	Costs	14
4.4	Conclusion	15
5	Recommendation for Treatment Strategy	15
5.1	Discussion	15
5.2	Recommendations to implement:	16
6	References	17

# 1 Introduction

The aim of this assignment is to evaluate treatment of hypercholesterolaemia with simvastatin and adjunct treatment with nutrients or herbs. One nutrient, fibre, is evaluated as a possible alternative treatment option for hypercholesterolaemia to simvastatin. At the end a general treatment recommendation is given.

## 2 Conventional Drug Therapy with Simvastatin

### 2.1 Pharmacology of ingredients

Simvastatin belongs to HMG-CoA reductase inhibitors (or statins), which competitively inhibit HMG-CoA, an enzyme that is rate limiting in cholesterol synthesis. Lowered cholesterol synthesis leads to increased clearance of LDL-cholesterol (LDL-C) from the blood (Bryant & Knights, 2007).

Additionally, Statins show anti-atherosclerotic properties such as decreased platelet aggregation, reduction of inflammatory processes and vasculoprotective properties. (Bryant & Knights, 2007; Kleemann & Kooistra, 2005)

Simvastatin is a pro-drug and is metabolized in the liver by CYP3A4 (part of cytochrome P450) to its active form in the first pass metabolism.

It can lower total cholesterol (TC) by 10% - 45% and increase HDL-cholesterol (HDL-C) by 2 – 13% (Bryant & Knights, 2007; Edwards & Moore, 2003).

A double-blind randomized placebo-controlled trial (DBRPC trial) of primary hypercholesterolaemic children at multiple centres showed that simvastatin statistically significantly lowered (TC) and LDL-C by 23.9% and 31.4% after 8 weeks and 30.9% and 40.7% after 48 weeks. However no significant changes in HDL-C levels were reported (de Jongh et al, 2002). A more recent DBRPC trial with children using pravastatin showed similar results (Wiegeman et al, 2004).

## 2.2 Main Indications and costs

Simvastatin is used in combination with dietary treatment for hypercholesterolemia and indicated in patients with high risk of developing coronary heart disease, including patients with past events of stroke, cerebrovascular or peripheral vessel disease, severe angina pectoris or diabetes. (MIMS, 2007).

Simvastatin is given 10 mg daily before bedtime, titrated monthly as needed up to 80 mg/day (Bryant & Knights, 2007).

The dispensed costs and the costs to the patient after the government subsidy are given in the table below on a monthly basis (PBS, 2008).

<u>Tablet Strength</u>	<u>Dispensed Cost per month</u>		<u>Cost to patient per month</u>	
	Generic in \$	Brand in \$	Generic in \$	Brand name in \$
5 mg	22.66	23.99	27.30	28.63
10 mg	29.23	30.56	31.30	36.63
20 mg	39.64	40.97	31.30	36.63
40 mg	54.65	55.99	31.30	36.63
80 mg	76.17	77.50	31.30	36.63

## 2.3 Safety Issues

### 2.3.1 Contraindications

Simvastatin is contraindicated in pregnancy and lactation, women of childbearing age unless they use effective contraception and in active liver disease (MIMS, 2007).

Bryant & Knights (2007) also mention the following contraindications:

- pre-existing liver / renal impairment;
- Severe intercurrent illness (infection, trauma);
- Prior to major surgery;
- Pregnancy.

### 2.3.2 Interactions

The main interaction with simvastatin are related to increased risk of myopathy if used in conjunction with certain antibiotics, anti-fungals or large doses of grapefruit juice (due to CYP3A4 interactions) or when using lipid lowering fibrates or niacin (Bryant & Knights, 2007; MIMS, 2007).

Inducers of CYP3A4 such as barbiturates, carbamazepine, phenytoin & griseofulvin cause a reduction of plasma level concentration of simvastatin (Bryant & Knights, 2007).

Simvastatin showed to increase the effect of warfarin (MIMS, 2007).

### 2.3.3 Adverse Reactions

Bryant & Knights (2007) list following adverse reactions:

- GIT discomfort, headaches, insomnia & dizziness;
- ↑ hepatic transaminase levels;
- Potential of myopathy with possible progress to rhabdomyolysis & renal failure.

## 3 Integrative Approach - Possible Interactions and Potentiations with Natural Medicine

### 3.1 Nutritional

#### 3.1.1 Fish Oil

- In a double blind, randomized, placebo controlled (DBRPC) studies, hyperlipidaemic patients on stable statin therapy showed that, addition of fish oils or omega-3-acid ethyl ester synergistically reduced triglyceride levels more than statin treatment only (Davidson et al, 2007; Durrington et al, 2001).
- A recent meta-analysis concluded that treatment with omega-3 fatty acids was a useful and safe adjunct to statin therapy to lower triglyceride levels (Nambi & Ballantyne, 2006).

#### 3.1.2 Co-Enzyme Q10

- A meta-analysis concluded that there is some evidence that the reduction of CoQ10

levels in statin treated patients is the reason for the development of myopathies, but also concluded that treatment with CoQ10 was safe (Marcoff & Thompson, 2007).

Noteworthy is that one of the authors received research support from as well as having own stocks in the pharmaceutical companies Merck, Pfizer and Schering-Plough.

- A small study of 18 patients with hypercholesterolemia, of which 8 exhibited muscle symptoms, concluded that statin drug related myopathy is associated with mild decrease in muscle CoQ10 concentration. (Lamperti et al, 2005).

- In a DBRPC clinical trial 32 subjects using statin treatment and reporting myopathic symptoms were either given 100 mg CoQ10/day or Vitamin E. 16 out of 18 patients in the CoQ10 group reported improvements. In average CoQ10 subjects showed a decrease of 40 % of pain severity and 38% pain interference. No change was evident in the control group. (Caso et al, 2007).

### 3.1.3 Policosanol

- A meta-analysis of policosanol research showed that the human studies showed a safe and effective action of policosanol. Efficacy was considered similar to statin drugs, including simvastatin. However the author also acknowledged that most of the research was done in Cuba using Cuban policosanol (Janikula, 2002).
- Two recent DBRPC trials have shown that the effect of policosanol (not of Cuban origin) on cholesterol levels was statistically not significant when using the same or higher dosages as in previous trials (Berthold et al, 2006; Dulin et al, 2006).
- Further research is necessary to make a definite statement.

### 3.1.4 Red Yeast Rice

- A meta-analysis of 93 trials using 3 different red yeast rice preparations (2 of them being a combination with other herbs) showed that all 3 of them lowered total cholesterol levels and 2 of them were equally effective as the tested statins. (Liu et al, 2006).
- Red Yeast Rice can have side-effects and is contraindicated in liver disease. Furthermore

no long term safety data is available yet (IMgateway, 2008).

### 3.1.5 Vit B<sub>3</sub> (Niacin)

- Niacin has been used since the 1950s and studies show that extended release niacin reduces TC and LDL-C significantly while raising HDL-C levels. (Braun & Cohen, 2007).
- Slow release niacin used in conjunction with statins in a 1053 patient trial that was prospective, observational and multicentred showed to be generally well tolerated and safe. Major complaints were flushing and sometimes pruritus, upper abdominal pain and nausea. HDL-C increased and triglycerides decrease significantly. LDL-C and TC changes were modest (Birjmohun et al, 2007).

### 3.1.6 Probiotics

- Various in vitro studies showed the potential of probiotics to reduce cholesterol (Brashears et al, 1998; Buck & Gilliland, 1994).
- There seems to be benefit of probiotics in reducing cholesterol levels depending on the strain of probiotics used but a recent systematic review highlights that a conclusive judgement is not possible (Lion, 2007).

### 3.1.7 Plant Sterols

- A review of studies concluded that sterols added to the diet are more effective than doubling statin medication. 2 g / day of sterols cause usually approx 9% decrease in LDL cholesterol. Sterols were added to margarine, their use was considered safe and absorption of lipid soluble vitamins



seemed to be unaffected except for beta-betacarotenes. It was concluded that this could be remedied by increasing intake of fruit and vegetables (Katan et al, 2003).

- A DBRPC study on 73 subject over 8 weeks with sterol enriched orange juice found that the test subject consuming the equivalent to 2 g sterols/day showed a 9.4% decrease in LDL-C and 6% increase in HDL-C, however comparing HDL-C increases between placebo and study group showed no significant difference. The tabular presentation of the data was not very clear. (Devaraj et al, 2004).
- The above review and the study were sponsored by corporations that have vested interests in positive outcomes for plant sterols.

### **3.1.8 Soy Protein**

- A meta analysis found that soy has some lipid lowering effects, especially if using soy-protein that is high in isoflavones as determined in a meta-analysis (Zhuo et al, 2004).
- A meta-analysis of 11 trials found that soy isoflavones significantly decreased TC by 1.77% and LDL-C by 3.58%. The amount of soy necessary to be eaten was approx. 230 g tofu or 2 glasses of soymilk daily (Taku et al, 2007).

## **3.2 Herbal**

### **3.2.1 Cynara scolymus**

- In vitro tests suggest that Cynara inhibits the synthesis of cholesterol (Mills & Bone, 2001).
- Cynara has hepatoprotective, hepatotrophorestorative, choloretic,

cholagogue, bitter tonic and hypocholesterolemic actions and clinical data from uncontrolled trials from 1936 to 1994 showed a capacity to reduce cholesterol/triglyceride levels in a range from 5% to 45% (Bone, 2003).

- More recent studies have sometimes been not quite conclusive but a German double-blind, randomized, placebo-controlled showed a decrease in LDL-cholesterol (Braun & Cohen, 2007).

### 3.2.2 Garlic

- Meta analyses and systemic reviews show ambivalent results when using garlic to lower cholesterol (some showed superiority to placebo, some not) which could be attributed to dosage and form of garlic preparations (Rahman and Lowe, 2006; Banerjee & Maulik, 2002).
- One meta –analysis (Stevinson et al 2001) found that garlic was superior to placebo treatment, however the reduction was modest.
- An open, non placebo controlled trial with 5 g raw garlic/day on 30 volunteers for a period over 42 days achieved a total cholesterol reduction of 11% and an increase of 10% in HDL-cholesterol (Mahmoodi et al, 2006).
- The evidence points to fresh garlic as a complimentary medicine for lowering blood cholesterol.

### 3.2.3 Commiphora mol mol

- The ingredient of interest is the oleo-gum-resin guggul (Braun & Cohen, 2007).
- The results of 6 randomized trials, 2 of which were placebo controlled, suggest that total serum cholesterol could be reduced ranging from 10% to 27% compared to baseline levels (Thompson Coon & Ernst, 2003).
- A DBRPC study with 103 subjects found that guggulipid in 1000 mg & 2000 mg doses given three times daily resulted in increased levels of LDL-cholesterol but 6 patients complained about sensitivity rashes (Szapary et al, 2005).
- Further research is necessary to establish a definite action.

## 4 Fibre as a Possible Natural Therapy Alternative

### 4.1 Efficacy

Water soluble fibre includes gums, mucilages, & most pectins contained in oat bran, psyllium, barley, fruit etc. whereas cellulose and lignins are non-soluble fibre (Williams & Schlenker, 2003; Jones, 2002).

Water soluble fiber has lipid lowering properties thought to be due to increased faecal bile acid excretion & interference with bile acid re-absorption. (Williams & Schlenker 2003; Jones, 2002). A trial measuring the level of  $\alpha$ -HC (a marker of bile acid synthesis) found that 8 hours after consumption of oat bran containing 11 g  $\beta$ -glucan the level of  $\alpha$ -HC went up significantly, meaning that the bile acid synthesis went up as well. (Andersson et al 2002).

Oat bran contains beta-glucans that are known for sequestering bile acids (Kohlmeier, 2003; Williams & Schlenker, 2003).

Thirty-six overweight men aged 50–75 y (normal TC & LDL-C) were randomly assigned to consume daily for 12 wk either oat or wheat cereal providing 14 g dietary fibre/day (= 5.5  $\beta$ -glucan). Diet control was a 4 day food intake diary at baseline and during the final week, no other dietary modifications were implemented The recorded reduction in LDL-C and the TC:HDL-C ratio were 2.5% and 6.3% in the study group. In the control group the LDL-C increased by 8.2% and TC:HDL-C by 12.2%. There was some inconsistency regarding the statistical significance, which could be due to the study sample size (Davy et al, 2002).

Pins et al (2002) conducted a similar study, with 88 subjects, all of them with hypertension (LDL-C & TC mildly elevated). Study subjects consumed either oat or wheat cereal for 12 weeks. No other dietary modifications were implemented in the double-blind randomized trial and diet control was a 3 day food record at baseline and during final week of study. The patients continued to take the blood pressure medication. The results showed that TC and LDL-C dropped by 15% and 16% in the oat group but only 3.5% and 4.4% in the wheat group. The statistical difference between the groups was considered significant.

Both studies were financed by the producers of the oat cereal product, which could have influenced the reporting.

Psyllium is often used as adjunct to low fat diet. A cholesterol lowering effect is to be expected after approx. 8 weeks (Braun & Cohen, 2007).

In a DBRPC trial over 26 weeks 248 female & male subjects (LDL-C and TC were mildly elevated) were given either 2 sachets of metamucil (= 5.1 g psyllium) following the AHA step I diet (limited fat & cholesterol) or cellulose. Blood samples were taken at the beginning and throughout the trial in regular intervals. In the test group TC and LDL-C levels reduced by 2.1% and 2.9%. This was reported as a significant difference of 4.7% and 6.7% compared to the cellulose group (Anderson et al, 2000). The study size was good, so the results can be considered reliable.

A study of 63 subjects (mainly female, TC mildly elevated, LDL-C still normal) found no significant influence of psyllium consumption and cholesterol levels. (Van Rosendaal, 2004). This study was not financed by a corporation with interest in the product tested. However, the fibre was only administered once a day, whereas in other studies, fibre was given 2 to 4 times a day. The dietary regimen of these patients is not quite clear, as some of them were given diets high in insoluble fibre beginning 1 month before start of trial. Furthermore the study did not have a control group.

A small study with 20 patients with DM II (mildly elevated TC & LDL-C) showed that subjects taking 14 g of psyllium husks divided over 4 doses throughout the day showed that TC significantly decreased by 7.7% and LDL-C by 9.2% after 2 weeks of psyllium husks. However this trial did not have a control group. (Sierra et al, 2002).

Morya et al (2005) conducted a DBRPC study with 68 male & female subjects on statin treatment (TC & LDL-C considerably elevated). 5.1 g psyllium tds and 1 statin tablet (10 mg) nocté was compared to a placebo tds and 1 statin tablet wither 10 mg or 20 mg nocté. After 8 weeks TC fell by 26% in psyllium/statin group compared to 24% in 20 mg simvastatin group. The drop in LDL-C was equal in both groups. Their study showed that a 10mg statin plus psyllium could achieve about the same results as 20 mg statin treatment. However, the

statistical significance in this trial is questionable, which could be due to the small size in each group (n=23 or n= 22).

In another study, low (0 g), medium (3 g) and high (6 g)  $\beta$ -glucan level diets were given to 25 subjects (TC and LDL-C mildly elevated) at randomized succession (Latin-Square Design) for 5 weeks for each diet after an initial 2-week base diet period. Results showed that the high  $\beta$ -glucan diet resulted in significant decreases in TC (10%) and LDL-C (17.4%) levels (Behall et al, 2004). This was the only researched study with a tightly controlled diet (subjects ate under supervision or had take-home food packs). In other cases researchers relied on food diaries etc. which are more open to errors and could affect study outcomes.

## 4.2 Adverse Effects of Fibre

- Bloating and flatulence are common complaints (Behall et al, 2002)
- In a study involving 20 subject that took 14 g fibre per day for 6 weeks, blood levels for Calcium, Phosphorus, Sodium, Potassium, Magnesium, Iron, Vitamin A and Vitamin E were not significantly changed between baseline and after 6 weeks. (Sierra et al, 2002).

## 4.3 Costs

- If using Psyllium husks:
  - Dosage: 4 – 5 g of psyllium husks in water 3-4 times per day, followed by glass of water (Braun & Cohen, 2007)
  - 500 g of Bonvit Psyllium Husks cost approx. \$9.96 (RRP)  $\rightarrow$  \$0.01992/g
  - Cost per day: 20 g x \$0.01992 = \$ 0.40/day  $\rightarrow$  \$11.95/month
- If using oats:
  - Study using oat cereal with approx. 6.23 g soluble fibre/day. 75 g Quaker oatmeal contains approx. 3.25 g soluble fibre (Pins et al, 2002)  $\rightarrow$  100 g oat meal or rolled oats = 5.42 g soluble fibre  $\rightarrow$  114.94 g of rolled oats daily
  - Price of Oats: 1 kg = approx. \$ 5.70  $\rightarrow$  costs = approx. \$0.65/day  $\rightarrow$  approx. \$19.50/month

## 4.4 Conclusion

In order to be a true alternative the natural therapy alternative should have similar or better efficacy in a similar or better time frame with similar or less adverse reactions.

Fibre certainly has less severe side effects than simvastatin and from that perspective is a preferable treatment option.

Changes in cholesterol levels become effective after 4 – 6 weeks when increasing the fibre intake (Braun & Cohen, 2007; Behall, 2002). Medication with Simvastatin takes approx. 4 weeks to take effects (Medscape, 2008). Both treatments are similar in onset of their effect.

Comparing the costs, fibre is approx. 28% (oats) – 56% (psyllium) cheaper. However, the patient might find it challenging to eat > 100g of oats / oatmeal every day.

In studies Simvastatin showed to reduce TC by approx. 25 % and LDL-C by approx. 34% in average (Edwards & Moore, 2003). Looking at the studies analysed above, fibre has the potential to reduce mildly elevated TC and LDL-C levels at best by 10% and 17.4 % in conjunction with a low fat diet (Behall et al, 2002)

It is important to mention that most studies examining the benefits of fibre in lowering cholesterol were financed by the manufacturers of fibre products or involved parties that had a vested interest in positive study outcomes. This doesn't mean that the results are wrong or that fibre is not beneficial, but could have skewed some of the reporting towards more favourable statements.

Overall fibre has a good potential as an adjunct therapy together with diet, but cannot be used alone to replace treatment with Simvastatin.

## 5 Recommendation for Treatment Strategy

### 5.1 Discussion

A good adjunct therapy should have established benefits and little or no side effects. From this perspective policosanol, guggulipids and red yeast rice are not good recommendations. Although niacin has well established benefits, the side effects can be still quite substantial (hot flushes, rashes etc.).

As outlined above fibre is a safe and low cost adjunct to simvastatin.

As assistance in lowering levels of triglycerides as well, fish oil is a good complement to statins. The dosage is 4 mg of omega-3 daily (Davidson et al, 2007). However, it has to be noted that in the trials mentioned earlier the patients were also following a low fat diet, which is likely to have influenced the results positively.

Garlic has shown to lower blood cholesterol even if the results are modest (Stevinson et al, 2001). As an adjunct therapy it would be beneficial if the patient does not object to the odour. As with fibre, garlic is not expensive and is safe. .

A study with 66 hyperlipidaemic patients combined various dietary cholesterol-lowering changes over a period of 12 months such as reduction of saturated fats and cholesterol, inclusion of 1.0 g plant sterol (as margarine), 10 g soluble fibre, 22.5 g soy protein and 23 g of whole almonds (Jenkins et al, 2006). The results showed a statistically highly significant mean reduction of 12.8% in LDL-C. However, 17% of the subjects left the study prematurely and cholesterol reduction was very closely linked to compliance. This study shows the beneficial effect of diet however stresses the problems of compliance often found with dietary changes if they are too radical.

## 5.2 Recommendations to implement:

- Take 2 fish capsules twice daily with meals
  - Incorporate approx. 3 cloves of raw garlic (bruised or crushed) into the diet daily
  - Take 4-5 g psyllium husks in water three times per day
  - Follow a diet that is similar to the American Heart Associations recommendations (AHA, 2008)
- Reduce total fat to 25-30% of total kilojoule intake, with saturated fat being < 7%, and cholesterol less than 200 mg per day.
  - Have approx. 15% protein per day, including some soy protein
  - Carbohydrates should be from whole grains, fruits and vegetables
  - Include moderate physical exercise daily



## 6 References

- American Heart Association, 2008, *Step I, Step II and TLC diets*, American Heart Association, viewed 17 April 2008, <http://www.americanheart.org/presenter.jhtml?identifier=4764>
- Anderson, JW, Davidson, MH, Blonde, L, Brown, WV, Howard, WJ, Howard, WJ, Ginsberg, H, Allgod, LD & Weingand, KW, 2000, 'Long-term cholesterol-lowering effects of psyllium as an adjunct to diet therapy in the treatment of hypercholesterolemia', *American Journal of Clinical Nutrition*, vol. 71, no. 6, pp. 1433-1438, viewed 16 April 2008, <http://www.ajcn.org/cgi/reprint/71/6/1433>
- Andersson, M, Ellegard, L & Andersson, H, 2002, 'Oat bran stimulates bile acid synthesis within 8 h as measured by 7 $\alpha$ -hydroxy-4-cholesten-3-one' *American Journal of Clinical Nutrition*, vol. 76, no. 5, pp 1111-1116, viewed 15 April 2008, <http://www.ajcn.org/cgi/reprint/76/5/1111>
- Banerjee, SK & Maulik, SK, 2002, 'Effect of garlic on cardiovascular disorders: a review', *Nutritional Journal*, viewed 28 March 2008, PUBMED database, Pubmed ID no: 12537594
- Behall, KM, Scholfield, DJ & Hallfrisch, J, 2004, 'Diets containing barley significantly reduce lipids in mildly hypercholesterolemic men and women', *American Journal of Clinical Nutrition*, vol. 80, no. 5, pp. 1185-1193, viewed 16 April 2008, <http://www.ajcn.org/cgi/reprint/80/5/1185>
- Berthold, HK, Unverdorben, S, Degenhardt, R, Bulitta, M & Gouni-Berthold, I, 2006, 'Effect of Policosanol on Lipid Levels Among Patients With Hypercholesterolemia or combine Hyperlipidemia', *Journal of American Medical Association*, vol. 295, no. 19, pp. 2262-2269, viewed 9 April 2007, <http://jama.ama-assn.org/cgi/content/full/295/19/2262>
- Birjmohun, RS, Kastelein, JJP, Poldermans, D, Stroes, ESG, Hostalek, U & Assmann, G, 2007, 'Safety and tolerability of prolonged-release nicotinic acid in statin-treated patients', *Current Medical Research and Opinion*, vol. 23, no. 7, pp 1707-1713, viewed 12 April 2008, ProQuest database Health and Medical Complete, ProQuest ID no 1313495361
- Brashears MM, Gilliland, SE & Buck, LM, 1998, 'Bile salt deconjugation and cholesterol removal from media by *Lactobacillus casei*', *Journal of Dairy Science*, vol. 81, no. 8, pp. 2103-2110, viewed 12 April 2008, PubMed, PMID 9749373
- Braun, L & Cohen, M, 2007, *Herbs & Natural Supplements. An Evidence Based Guide*, 2<sup>nd</sup> edn., Churchill Livingstone, Sydney
- Bryant, B & Knights, K, 2007, *Pharmacology for Health Professionals*, 2<sup>nd</sup> ed., Mosby Elsevier, Sydney
- Buck, LM & Gilliland, DE, 1994, 'Comparisons of freshly isolated strains of *Lactobacillus acidophilus* of human intestinal origin for ability to assimilate cholesterol during growth', *Journal of Dairy Science*, vol. 77, no. 10, pp. 2925-2933, viewed 12 April 2008, PubMed, PMID 7836579
- Caso, G, Kelly, P, McNurlan, MA, Lawson, WE, 2007, 'Effect of Coenzyme Q10 on Myopathy Symptoms in Patients Treated with Statins', *American Journal of Cardiology*, vol. 99, no. 10, pp. 1409 – 1412, viewed 25 March, 2007, <http://download.journals.elsevierhealth.com/pdfs/journals/0002-9149/PIIS000291490700255X.pdf>
- Davidson, MH, Stein, EA, Bays, HE, Maki, KC, Doyle, RT, Shalwitz, RA, Ballantyne, CM & Ginsberg, HN, 2007, 'Combination of prescription Omega-3 with Simvastatin (COMBOS) Investigators', *Clinical Therapy*, vol. 29, no. 7, pp. 1354-1367, viewed 11 April 2008, PubMed, PMID: 17825687
- Davy, BM, Davy, KP, Ho, RC, Beske, SD, Davrath, LR & Melby, CL, 2002, 'High-fiber oat cereal compared with wheat cereal consumption favorably alters LDL-cholesterol subclass

- and particle numbers in middle-aged and older men', *American Journal of Clinical Nutrition*, vol 76, no. 2, pp. 351-358, viewed 16 April 2008, <http://www.ajcn.org/cgi/reprint/76/2/351>
- De Jongh, s, Ose, L, Szamosi, T, Gane, C, Lamber, M, Scott, R, Perron, P, Dobbelaere, D, Saborio, M, Tuohy, MB, Stepanavage, M, Sapre, A, Gumbiner, B, Mercuri, M, van Trotsenburg, AS, Bakker, HD, Kastelein, JJ & Simvastatin in Children Study Group 2002, 'Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin', *Circulation*, vol. 106, no. 17, pp. 2231-2237, viewed 24 April 2008, <http://circ.ahajournals.org/cgi/content/full/106/17/2231>
- Devarai, S & Jialal, I, 2006, 'The Role of Dietary Supplementation with Plant Sterols and Stanols in the Prevention of Cardiovascular Disease', *Nutrition Reviews*, vol 64, no. 7, pp. 348-354, viewed 12 April 2008, ProQuest Health Module database, ProQuest Id no 1122409781
- Devaraj S, Autret, B & Jialal, I, 2006, 'Reduced-calorie orange juice beverage with plant sterols lowers C-reactive protein concentrations and improves the lipid profile in human volunteers', *American Journal of Clinical Nutrition*, vol. 84, no 4, pp. 756-762, viewed 26 March 2008, <http://www.ajcn.org/cgi/reprint/84/4/756>
- Devaraj S, Jialal I & Vega-López S, 2004, 'Plant sterol-fortified orange juice effectively lowers cholesterol levels in mildly hypercholesterolemic healthy individuals', *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 24, no. 3, pp. 25-28, viewed 26 March 2008, <http://atvb.ahajournals.org/cgi/reprint/24/3/e25>
- Dulin, MF, Hatcher, LF, Sasser, HC & Barringer, TA, 2006, 'Policosanol is ineffective in the treatment of hypercholesterolemia: a randomized controlled trial', *American Journal of Clinical Nutrition*, vol. 84, no. 6, pp. 1543-1548, viewed 9 April 2008, PUBMED, PMID 17158441
- Durrington, PN, Bhatnaga, D, Mackness, MI, Morgan, J, Julier, K, Khan, MA & France, M 2001, 'An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia', *Heart*, vol. 85, no. 5, pp. 544-548, viewed 24 April 2008, PubMed Central, PMCID: PMC1729738
- Edwards, JE & Moore, RA, 2003, 'Statins in hypercholesterolaemia: A dose-specific meta-analysis of lipid changes in randomised, double blind trials', *BMC Family Practice*, vol. 4, viewed 30 March 2008, PubMed Central, PMC Id: PMC317299.
- Eggertsen, R, Andreasson, A & AndrénL, 2007, 'Effects of treatment with a commercially available St John's Wort product (Movina®) on cholesterol levels in patients with hypercholesterolemia treated with simvastatin', *Scandinavian Journal of Primary Health Care*, vol. 25, no. 3. pp.154-159, viewed 25 March, 2008, <http://www.informaworld.com/10.1080/02813430701442768>
- Eggertsen, R, Andreasson, A & AndrénL, 2007, 'Effects of treatment with a commercially available St John's Wort product (Movina®) on cholesterol levels in patients with hypercholesterolemia treated with simvastatin', *Scandinavian Journal of Primary Health Care*, vol. 25, no. 3. pp.154-159, viewed 25 March, 2008, <http://www.informaworld.com/10.1080/02813430701442768>
- IMgateway, 2008, *Reference Database: Red Yeast Rice*, UnityHealth Proprietary Limited, viewed 10 April 2008, [www.imgateway.net](http://www.imgateway.net)
- Janikula, M, 2002, 'Policosanol a new treatment for cardiovascular disease?', *Alternative Medicine Review*, vol. 7, no. 3, pp. 203-217, viewed 12 April 2008, PubMed, PMID: 12126462
- Jenkins, DJ, Kendall, CW, Marchie, A, Faulkner, DA, Wong, JM, de Souza, R, Emam, A, Parker, TL, Vidgen, E, Trautwein, EA, Lapsley, KG, Josse, RG, Leiter, LA, Singer, W & Connelly PW, 2005, 'Direct comparison of a dietary portfolio of cholesterol-lowering foods

- with a statin in hypercholesterolemic participants', *American Journal of Clinical Nutrition*, vol. 81, no. 2, pp. 380-387, viewed 16 April, 2008, <http://www.ajcn.org/cgi/reprint/81/2/380>
- Jones, PT, 2002, 'Clinical nutrition: 7. Functional foods – more than just nutrition', *Journal of Canadian Medical Association*, vol. 166, no. 12, pp. 1555-1563, viewed 12 April, 2008, PubMed Central, ID PMC113804
- Katan, MB, Grundy, SM, Jones, P, Law, M, Miettinen, T & Paoletti, R, 2003, 'Efficacy and Safety of Plant Stanols and Sterols in the Management of Blood Cholesterol Levels', *Mayo Clinic Proceedings*, vol. 78, no. 8, pp. 965-p, viewed 12 April, 2008, ProQuest Health and Medical Complete database, ProQuest Id no 383865681.
- Kleemann, R & Kooistra, T, 2005, '.HMG-CoA reductase inhibitors: effects on chronic subacute inflammation and onset of atherosclerosis induced by dietary cholesterol', *Current Drug Targets. Cardiovascular and Haematological Disorders.*, vol. 5, no. 6, pp.441-453, viewed 2 April, 2008, PubMed, PMID: 16503864.
- Kohlmeier, M, *Nutrient Metabolism*, Academic Press Elsevier, Sydney
- Lamperti, C, Naini, AB, Lucchini, V, Prella, A, Bresolin, C, Moggio, M, Sciacco, M, Kaufmann, P & DiMauro, S, 2005 'Muscle Coenzyme Q10 Level in Statin-Related Myopathy', *Archives of Neurology*, vol. 62, no. 11, pp. 1709-1712, viewed 25 March 2008, <http://archneur.ama-assn.org/cgi/reprint/62/11/1709>
- Liong, MT, 2007, 'Probiotics a Critical Review of Their Potential Roles a Antihypertensives, Immune Modulators, Hypocholesterolemic, Perimenopausal Treatments', *Nutritional Reviews*, vol. 65, no. 7, pp. 316-329, viwed 12 April 2008, ProQuest Health Module database, ProQuest ID no 1315956031
- Liu, J, Zhang, J, Shi, Y, Grimsgaar, S, Alraek, T & Fonnebo, V, 2006, 'Chinese red yeast rice (*Monascus purpureus*) for primary hyperlipidemia: a meta-analysis of randomized controlled trials', *Chinese Medicine*, vol. 1, no. 4, pp. 1-13, PubMed, PMID: 17302963
- Mahmoodi M, Islami MR, Asadi Karam GR, Khaksari M, Sahebghadam Lotfi A, Hajizadeh MR & Mirzaee MR, 2006, 'Study of the Effects of Raw Garlic Consumption on the Levels of Lipids and Other Blood Biochemical Factors in Hyperlipidemic Individuals', *Pakistan Journal of Pharmaceutical Science*, vol. 19, no. 4, pp. 295-298, viewed 28 March 2008, <http://www.pjps.pk/PJPS-19-4-06/Paper-6.pdf>
- Marcoff, L & Thompson PD, 2007, 'the role of coenzyme Q10 in statin-associated myopathy:a systematic review', *Journal of the American College of Cardiology*, vol. 49, no. 23, pp. 2231-2237, viewed 11 April, 2008, PubMed, PMID: 17560286
- Medscape, 2008, *Simvastatin: Oral: Patient Information*, WebMD Health Professional Network, viewed 18 April 2008, <http://www.medscape.com/druginfo/patienthandout?cid=med&drugid=6105&drugname=Simvastatin+Oral&monotype=patienthandout>
- Moreyra, AE, Wilson, AC & Koraym, A, 2005, 'Effect of Combining Psyllium Fiber With Simvastatin in Lowering Cholesterol; *Archives of Internal Medicine*, vol. 165, no. 10, pp. 1161-1166, viewed 16 April, 2008, <http://archinte.highwire.org/cgi/reprint/165/10/1161>
- Nambi, V & Ballantyne, CM, 2006, 'Combination therapy with statins and omega-3 fatty acids', *The American Journal of Cardiology*, vol. 98, no 4A, pp. 34i-38i, viewed 11 April 2008, PubMed, PMID: 16919515
- PBS, 2008, PBS for Health Professionals, *Australian Government, Department of Health and Ageing*, viewed 2 April 2007, <http://www.pbs.gov.au/html/healthpro/search/results?term=simvastatin&&scope=PBS%20STATIN&form-type=simple&page=1>
- Pizzorno Jr, JE & Murray MT, 2006, *Textbook of Natural Medicine*, 3edn., Churchill Livingstone Elsevier, St. Louis, Missouri

Rahman, K & Lowe, GM, 2006, 'Garlic and Cardiovascular Disease: A Critical Review', *Journal of Nutrition*, vol. 136, no. 3, pp. 736S-740S, viewed 28 March 2008, <http://jn.nutrition.org/cgi/reprint/136/3/736S>

Robert Reid, R, Fodor, G, Lydon-Hassen, K, D'Angelo, MS, et al. (2002). 'Dietary counselling for dyslipidemia in primary care: Results of a randomized trial', *Canadian Journal of Dietetic Practice and Research*, vol. 63, no. 4, pp. 169-176, viewed 17 April 2008, ProQuest Health and Medical Complete database, ProQuest id: 265943661.

Sierra, M, Garcia, JJ, Fernandez, N, Diez, MJ & Calle, AP, 2002, 'therapeutic effects of psyllium in type 2 diabetic patients', *European Journal of Clinical Nutrition*, vol. 56, no. 9, pp. 830-842, viewed 17 April 2008, <http://www.nature.com/ejcn/journal/v56/n9/pdf/1601398a.pdf>

Stevinson C, Pittler, MH & Ernst, E, 2001, 'Garlic for treating hypercholesterolemia. A meta-analysis of randomized clinical trials', *Annals of Internal Medicine*, vol. 133, no. 6, pp. 420 - 429, viewed 9 April 2008, <http://annals.highwire.org/cgi/reprint/133/6/420.pdf>

Szapary, PO, Wolfe, ML, Bloedon, LT, Cucchiara, AJ, DerMarderosian, AH, Cirigliano, MD & Rader, DJ, 2005, 'Guggulipid for the Treatment of Hypercholesterolemia: A Randomized Controlled Trial', *Journal of American Medical Association*, vol. 290, no. 6, pp. 765-772

Taku, K, Umegaki, K, Sato, Y, Taky, Y, Endoh, K & Watanabe, S, 2007, 'Soy isoflavones lower serum total and LDL cholesterol in humans: a meta-analysis of 11 randomized controlled trials', *The American Journal of Clinical Nutrition*, vol. 68, pp. 1385S-1389S, viewed 16 April 2008, <http://www.ajcn.org/cgi/reprint/68/6/1385S>

Thompson Coon, JS & Ernst, E, 2003, 'Herbs for serum cholesterol reduction: a systematic view', *The Journal of Family Practice*, vol. 52, no. 6, pp. 468-478, viewed 9 April, 2007, PubMed, PMID: 12791229

Van Rosendaal, GM, Shaffer, EA, Edwards, AL, & Brant, R, 2004, 'Effect of time of administration on cholesterol-lowering by psyllium: a randomized cross-over study in normocholesterolemic or slightly hypercholesterolemic subjects' *Nutrition Journal*, vol. 3, no. 17, viewed 16 April 2008, PubMed, PMID 15453909

Wiegeman, A, Hutten, BA, de Groot, E, Rodenburg, J, Bakker, HD, Buller, HR, Sijbrands, EJM & Kastelein, JJP 2004, 'Efficacy and Safety of Statin Therapy in Children With Familial Hypercholesterolemia', *Journal of American Medical Society*, vol. 291, no. 3, pp. 331-337 viewed 24 April 2008, <http://jama.ama-assn.org/cgi/reprint/292/3/331>

Williams, SR & Schlenker, ED, 2003, *Essentials of Nutrition and Diet Therapy*, Mosby, St. Louis, Missouri

Zhuo, XG, Melby, MK & Watanabe, S, 2004, 'Soy isoflavone intake lowers serum LDL cholesterol: a meta-analysis of 8 randomized controlled trials in humans', *The Journal of Nutrition*, vol. 134, no. 9, pp. 2395-2400, viewed 10 April 2008, <http://jn.nutrition.org/cgi/reprint/134/9/2395>